CareCloud (CCLD) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We operate in a highly competitive industry, and our competitors may be able to compete more efficiently or evolve more rapidly than we do, which could have a material adverse effect on our business, revenue, growth rates and market share
2. 02If we are unable to successfully introduce new products or services or fail to keep pace with advances in technology, we would not be able to maintain our customers or grow our business, which will have a material adverse effect on our business
3. 03The continued success of our business model is heavily dependent upon our offshore operations, and any disruption to those operations will adversely affect us
4. 04Our offshore operations expose us to additional business and financial risks which could adversely affect us and subject us to civil and criminal liability
5. 05We may be adversely affected by global climate change or market responses to such change
6. 06Changes in the healthcare industry could affect the demand for our services and may result in a decrease in our revenues and market share
7. 07If providers do not purchase our products and services or delay in choosing our products or services, we may not be able to grow our business
8. 08If the revenues of our customers decrease, or if our customers cancel or elect not to renew their contracts, our revenue will decrease
9. 09As a result of our variable sales and implementation cycles, we may be unable to recognize revenue from prospective customers on a timely basis and we may not be able to offset expenditures
10. 10We are required to collect sales and use taxes on certain products and services we sell in certain jurisdictions. We may be subject to liability for past sales and incur additional related costs and expenses, and our future sales may decrease
11. 11If the federal government were to impose a tax on imports or services performed abroad, we might be subject to additional liabilities. At this time, there is no way to predict whether this will occur or estimate the impact on our business
12. 12If we lose the services of Mahmud Haq as Executive Chairman, A. Hadi Chaudhry and Stephen Snyder as Co-Chief Executive Officers, or other members of our management team, or if we are unable to attract, hire, integrate and retain other necessary employees, our business would be harmed
13. 13We may be unable to adequately establish, protect or enforce our patents, trade secrets and other intellectual property rights and we may incur significant costs in enforcing our intellectual property rights
14. 14Claims by others that we infringe or may infringe on their intellectual property could force us to incur significant costs or revise the way we conduct our business
15. 15Current and future litigation against us could be costly and time-consuming to defend and could result in additional liabilities
16. 16Our proprietary software or service delivery platform may not operate properly, which could damage our reputation, give rise to claims against us, or divert application of our resources from other purposes, any of which could harm our business and operating results
17. 17If our security measures are breached or fail and unauthorized access is obtained to a customer’s data, our service may be perceived as insecure, the attractiveness of our services to current or potential customers may be reduced, and we may incur significant liabilities
18. 18Our products and services are required to meet the interoperability standards, which could require us to incur substantial additional development costs or result in a decrease in revenue
19. 19Disruptions in internet or telecommunication service or damage to our data centers could adversely affect our business by reducing our customers’ confidence in the reliability of our services and products
20. 20We may be subject to liability for the content we provide to our customers and their patients
21. 21We are subject to the effect of payer and provider conduct that we cannot control and that could damage our reputation with customers and result in liability claims that increase our expenses
22. 22Failure by our clients to obtain proper permissions and waivers may result in claims against us or may limit or prevent our use of data, which could harm our business
23. 23As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting
24. 24We may not be able to negotiate a credit facility at reasonable terms as the current credit facility expires in October 2025
25. 25We maintain our cash at financial institutions, often in balances that exceed federally insured limits
26. 26Our goodwill was subject to impairment in 2023 and may be subject to further impairment in the future, which could have a material adverse effect on our results of operations, financial condition, or future operating results
27. 27We are a party to several related-party agreements with our founder and Executive Chairman, Mahmud Haq, which have significant contractual obligations. These agreements are reviewed by our Audit Committee on an annual basis
28. 28We depend on key information systems and third-party service providers
29. 29Systems failures, cyberattacks or other events and resulting interruptions in the availability of or degradation in the performance of our websites, applications, products or services could harm our business
30. 30Data privacy, identity protection and information security compliance may require significant resources and presents certain risks
31. 31We use artificial intelligence in our business, and challenges with properly managing its use could result in reputational and competitive harm, legal liability, and adversely affect our results of operations
32. 32Rapid technological change in the telehealth industry presents us with significant risks and challenges
33. 33Our business, financial condition, results of operations and growth may be adversely affected by pandemics, epidemics or other public health emergencies, such as COVID-19

Risks Related to Macroeconomics Conditions

1. 34Our operations and performance depend significantly on global and regional economic conditions and adverse economic conditions can materially adversely affect our business, results of operations and financial conditions
2. 35Our managed medical practices and customers could face supply chain issues that would disrupt their ability to service patients and therefore, impact our revenue
3. 36Volatility in currency exchange rates may adversely affect our financial condition, results of operations and cash flows

Risks Related to Our Acquisition Strategy

1. 37If we do not manage our acquisitions effectively, our revenue, business and operating results may be harmed
2. 38We may be unable to implement our strategy of acquiring additional companies
3. 39At the current prices of our common and Preferred Stock, we may be unable to execute accretive acquisitions
4. 40We may be unable to retain customers following their acquisition, which may result in a decrease in our revenues and operating results
5. 41Acquisitions may subject us to liability with regard to the creditors, customers, and shareholders of the sellers
6. 42Future acquisitions may result in potentially dilutive issuances of equity securities, the incurrence of indebtedness and increased amortization expense

Regulatory Risks

1. 43The healthcare industry is heavily regulated. Our failure to comply with regulatory requirements could create liability for us, result in adverse publicity and negatively affect our business
2. 44If we do not maintain the certification of our EHR solutions pursuant to the HITECH Act and Cures Act, our business, financial condition and results of operations will be adversely affected
3. 45If a breach of our measures protecting personal data covered by HIPAA or the HITECH Act occurs, we may incur significant liabilities
4. 46Potential healthcare reform and new regulatory requirements placed on our products and services could increase our costs, delay or prevent our introduction of new products or services, and impair the function or value of our existing products and services
5. 47Additional regulation of the disclosure of medical information outside the United States may adversely affect our operations and may increase our costs
6. 48Our services present the potential for embezzlement, identity theft, or other similar illegal behavior by our employees

Risks Related to Ownership of Shares of Our Common Stock

1. 49The conversion of the Series A Preferred Stock into common stock in March 2025 (the "Conversion") increased the total number of outstanding shares, potentially diluting the value of existing common shareholders’ equity
2. 50Series A Preferred Stock shareholders gained full voting rights upon conversion of their preferred shares into common stock
3. 51The conversion of the Series A Preferred Stock could be perceived negatively by the market
4. 52The Company’s potential for future issuances of common stock following the Conversion could be limited
5. 53Our revenues, operating results and cash flows may fluctuate in future periods and we may fail to meet investor expectations, which may cause the price of our common stock to decline
6. 54Healthcare reform may have a material adverse effect on the Company’s financial condition and results of operations
7. 55Future sales of shares of our common stock could depress the market price of our common stock
8. 56As of December 31, 2024, Mahmud Haq controlled 31% of our outstanding shares of common stock, which prevented investors from influencing significant corporate decisions
9. 57Provisions of Delaware law, of our amended and restated charter and amended and restated bylaws may make a takeover more difficult, which could cause our common stock price to decline
10. 58Any issuance of additional preferred stock in the future may dilute the rights of our existing stockholders
11. 59Complying with the laws and regulations affecting public companies will increase our costs and the demands on management and could harm our operating results
12. 60We are a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors

Risks Related to Ownership of Shares of Our Preferred Stock

1. 61As a result of the Conversion, there may not be an organized trading market for the Series A Preferred Stock
2. 62Our Series A and Series B Preferred Stock rank junior to all of our indebtedness and other liabilities
3. 63We may issue additional shares of Preferred Stock and additional series of preferred stock that rank on parity with the Preferred Stock as to dividend rights, rights upon liquidation or voting rights
4. 64Market interest rates may materially and adversely affect the value of the Preferred Stock
5. 65Holders of the Preferred Stock may be unable to use the dividends-received deduction and may not be eligible for the preferential tax rates applicable to “qualified dividend income”
6. 66Our Preferred Stock has not been rated
7. 67The market price of our Series B Preferred Stock is variable and is substantially affected by various factors
8. 68A holder of Preferred Stock has extremely limited voting rights
9. 69The Preferred Stock is not convertible at the option of the holder, and investors will not realize a corresponding upside if the price of the common stock increases
10. 70Although payment of the suspended dividends resumed in February 2025, there are still dividends in arrears and we may be unable to raise additional capital without incurring excessive dilution